With various PTPs, such as PTP1B [29], currently the subject of intense drug discovery efforts in the context of obesity and insulin resistance, specific DUSP family members found to control MAPK dependent obesity, inflammation and insulin resistance may represent potential targets in the treatment of metabolic disease. Here, DUSP5 is linked to metabolic disease.